Results 61 to 70 of about 1,674,597 (262)

A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer [PDF]

, 2016
Our aim was to systematically evaluate the benefits of degarelix as antagonist versus agonists of gonadotropin-releasing hormones (GnRH) for the treatment of advanced prostate cancer (PC).
CATTARINO, SUSANNA, CIARDI, Antonio, Fasulo, Andrea, GENTILE, Vincenzo, GENTILUCCI, ALESSANDRO, INNOCENZI, MICHELE, Maggi, Martina, PETRANGELI, Elisa, PIERELLA, FEDERICO, SALCICCIA, STEFANO, SCIARRA, Alessandro   +10 more
core   +1 more source

Integrated genomic and proteomic profiling reveals insights into chemoradiation resistance in cervical cancer

Molecular Oncology, EarlyView.
A comprehensive genomic and proteomic analysis of cervical cancer revealed STK11 and STX3 as a potential biomarkers of chemoradiation resistance. Our study demonstrated EGFR as a therapeutic target, paving the way for precision strategies to overcome treatment failure and the DNA repair pathway as a critical mechanism of resistance.
Janani Sambath, Irene A. George, Srikanth S. Manda, Prasanth Ariyannur, Ekta R. Dhawale, Raja Sekhar Kommu, Rajan Datar, Darshana Patil, Vinita Trivedi, Manisha Singh, Kumar Prabhash, Sewanti Limaye, Richa Chauhan, Prashant Kumar   +13 more
wiley   +1 more source

Diagnostic criteria for primary progressive multiple sclerosis: A position paper

Annals of Neurology, 2000
The unique clinical characteristics of primary progressive multiple sclerosis (PPMS) pose particular diagnostic difficulties, both in excluding other causes of progressive syndromes and in confirming the diagnosis of MS, which is not adequately addressed by current diagnostic criteria.
Thompson AJ, Montalban X, Barkhof F, Brochet B, FILIPPI , MASSIMO, Miller DH, Polman CH, Stevenson VL, McDonald WI   +8 more
openaire   +4 more sources

Empirical progression criteria thresholds for feasibility outcomes in HIV clinical trials: a methodological study. [PDF]

Pilot Feasibility Stud, 2023
Mbuagbaw L, Chen LH, Aluko E, Stevens-Uninsky M, Eze-Onuorah ACJ, Garcia MC, Stech L, Atkin-Jones T, Rehman N, Raifu A.   +9 more
europepmc   +1 more source

Gut microbiota diversity is prognostic in metastatic hormone receptor‐positive breast cancer patients receiving chemotherapy and immunotherapy

Molecular Oncology, EarlyView.
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern, Kristian Holm, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Corinna Bang, Bjørn Naume, Johannes R. Hov, Jon Amund Kyte   +7 more
wiley   +1 more source

Interim evaluation of lifelong learning networks [PDF]

, 2008
The Open University's Centre for Higher Education Research and Information was commissioned in June 2007 to undertake a formative evaluation of Lifelong Learning Networks (LLNs).
Little, Brenda, Williams, Ruth
core  

Recommendations for progression criteria during external randomised pilot trial design, conduct, analysis and reporting. [PDF]

Pilot Feasibility Stud, 2023
Mellor K, Albury C, Dutton SJ, Eldridge S, Hopewell S.   +4 more
europepmc   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

Set up and assessment of progression criteria for internal pilots: the Brushing RemInder 4 Good oral HealTh (BRIGHT) trial example. [PDF]

Pilot Feasibility Stud, 2023
Ainsworth H, Marshman Z, Whiteside K, Sykes D, Fairhurst C, Turner E, Chestnutt I, Day P, Dey D, Elliott L, El-Yousfi S, Hewitt C, Jones C, Pavitt S, Robertson M, Torgerson D, Innes N.   +16 more
europepmc   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source